{"id":239686,"date":"2026-06-26T06:32:15","date_gmt":"2026-06-26T11:32:15","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/06\/car-t-cell-therapy-leads-to-10-year-remissions-in-b-cell-lymphoma-patients"},"modified":"2026-06-26T06:32:15","modified_gmt":"2026-06-26T11:32:15","slug":"car-t-cell-therapy-leads-to-10-year-remissions-in-b-cell-lymphoma-patients","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/06\/car-t-cell-therapy-leads-to-10-year-remissions-in-b-cell-lymphoma-patients","title":{"rendered":"CAR T cell therapy leads to 10-year remissions in B-cell lymphoma patients"},"content":{"rendered":"

<\/a><\/p>\n

After a median follow-up of 10 years, more than one-third of patients with large B-cell lymphoma and nearly half of patients with follicular lymphoma who received a single infusion of tisagenlecleucel\u2014the CAR T-cell therapy developed by Carl June, MD, that would go on to become the first such treatment approved by the FDA <\/a>\u2014were still alive without a lymphoma relapse, according to long-term follow-up data published in New England Journal of Medicine<\/i><\/a> by researchers from the Abramson Cancer Center and Perelman School of Medicine at the University of Pennsylvania.<\/p>\n

In the analysis of 38 patients from a Phase II clinical trial (including 24 patients with large B-cell lymphoma and 14 with follicular lymphoma) conducted at Penn Medicine\u2019s Abramson Cancer Center, no patients experienced a relapse after 5.4 years, and most relapses occurred within the first year after CAR T-cell infusion, supporting the hypothesis that patients who experience a long-term response to CAR T-cell therapy may be cured.<\/p>\n

\u201cAs oncologists, we use the word \u2018cure\u2019 with great care, but I am increasingly confident that CAR T-cell therapy has the potential to cure a meaningful number of patients with B-cell lymphomas,\u201d said senior author Stephen J. Schuster, MD, the Robert and Margarita Louis-Dreyfus Professor in Chronic Lymphocytic Leukemia and Lymphoma Clinical Care and Research and director of Penn\u2019s Lymphoma Program.<\/p>\n","protected":false},"excerpt":{"rendered":"

After a median follow-up of 10 years, more than one-third of patients with large B-cell lymphoma and nearly half of patients with follicular lymphoma who received a single infusion of tisagenlecleucel\u2014the CAR T-cell therapy developed by Carl June, MD, that would go on to become the first such treatment approved by the FDA \u2014were still [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-239686","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/239686","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=239686"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/239686\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=239686"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=239686"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=239686"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}